NIVF AI Price Prediction
Track NIVF's AI-powered predictions, market trends, and investment insights.
Mock Tradesimulated, no real money
You don't hold NIVF in your mock portfolio yet.
Track NIVF's AI-powered predictions, market trends, and investment insights.
You don't hold NIVF in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedThe extremely low PE ratio and very high EPS relative to the share price suggest either unusually strong reported earnings or, more likely, a major distortion (e.g., one‑off gains, accounting changes, reverse split history, or market skepticism about the sustainability of earnings). With only PE and EPS provided and no revenue or margin history, it is difficult to conclude that the underlying business is performing strongly on a recurring basis. The market’s deep discount to reported earnings implies investors are not yet convinced about the quality, durability, or transparency of those earnings.
The stock has dropped 37.7% in the last month and is trading massively below its 200‑day moving average of $29.77 at a current price of $0.56. Such a collapse relative to the long‑term average typically reflects severe negative sentiment, structural issues, or corporate events (e.g., reverse splits, dilutions, or restructuring). Technically, the trend is decisively down, and the long‑term chart is likely broken, even if short‑term oversold conditions may occasionally trigger brief rebounds.
NewGenIvf Group’s Facebook following of 1,752 with only 0.1% growth over 90 days points to a relatively small and slowly expanding social media footprint. This limited engagement does not suggest strong brand momentum or rapidly growing consumer interest at this time. In the absence of stronger signals from website traffic, app downloads, or hiring trends, social media data currently offers only a modest and largely neutral read‑through for the stock.
Overall, the setup for NewGenIvf Group appears bearish: the stock has suffered a sharp recent decline and trades far below its 200‑day moving average, indicating a broken long‑term trend and weak investor confidence. Although the reported PE and EPS metrics look extraordinarily cheap on the surface, the market’s willingness to price the stock at this level suggests deep skepticism about earnings quality or sustainability. With only modest and stagnant alternative data signals, there is little evidence of strong underlying momentum to counteract the negative technical picture.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
NewGenIVF Group (NIVF) is under notable pressure in 2026, posting an 8.9% single-session decline to $1.02 against unusually elevated trading volume of nearly 3 million shares. For a stock with a market capitalization of just $579,816, that volume figure is disproportionately large, suggesting speculative or forced activity rather than fundamental-driven interest. The Bangkok-headquartered IVF and surrogacy services provider sits deep in micro-cap territory, where liquidity risk and price swings are amplified. The sharp intraday move comes with no corresponding Reddit discussion in the past 24 hours, indicating the selling pressure is not retail-sentiment driven.
TrendEdge's AI model assigns NIVF a score of just 2 out of 10, reflecting a weak overall signal profile. The three primary drivers flagged are price momentum, elevated volatility, and Reddit activity — or more precisely, the absence of it. The average true range is running at 1.5 times normal levels, a quantitative marker of heightened instability. While the stock did record a 13.3% gain in the prior week, that move has now partially reversed, a pattern the AI model treats cautiously rather than as confirmation of a trend. A score of 2/10 places NIVF among the weakest-ranked equities on the TrendEdge platform.
Looking ahead, investors should monitor whether NIVF's volume surge resolves into sustained directional movement or simply reflects short-term noise around a thinly traded micro-cap. Key risks include the stock's sub-$600K market cap, which creates extreme sensitivity to even modest sell orders. Any catalyst — such as a clinical update, regulatory development in Thailand's fertility services sector, or a broader shift in small-cap sentiment — could trigger outsized moves in either direction given the current ATR environment.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
0
News Mentions
0
Key Metrics
